Death By 1,000 Cuts: How Republicans Can Still Alter Your Coverage
From the article:
“It’s the single-biggest problem facing the exchanges,” said Rachel Sachs, a health law professor at Washington University in St. Louis. “That would make insurers not only exit tomorrow but also not want to offer plans in 2018.”
Read more here!
Read the full article
Tags
biotechnology fda health care finance health care reform health law policy pharmaceuticals rachel sachs regulation